StockNews.com cut shares of Acacia Research (NASDAQ:ACTG – Free Report) from a hold rating to a sell rating in a research report report published on Wednesday.
Acacia Research Stock Performance
NASDAQ ACTG opened at $4.37 on Wednesday. Acacia Research has a fifty-two week low of $3.66 and a fifty-two week high of $5.74. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.95 and a current ratio of 16.39. The firm has a market capitalization of $425.50 million, a P/E ratio of 8.25 and a beta of 0.52. The stock has a 50-day simple moving average of $4.44 and a two-hundred day simple moving average of $4.70.
Insider Activity
In other Acacia Research news, Director Isaac T. Kohlberg sold 15,000 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $4.57, for a total transaction of $68,550.00. Following the transaction, the director now owns 69,274 shares of the company’s stock, valued at approximately $316,582.18. The trade was a 17.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.65% of the company’s stock.
Hedge Funds Weigh In On Acacia Research
About Acacia Research
Acacia is a publicly traded (Nasdaq: ACTG) company that is focused on acquiring and operating businesses across the industrial, energy and technology sectors where it believes it can leverage its expertise, significant capital base, and deep industry relationships to drive value. Acacia evaluates opportunities based on the attractiveness of the underlying cash flows, without regard to a specific investment horizon.
Featured Articles
- Five stocks we like better than Acacia Research
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- 3 Defensive Stocks Analysts Are Bullish on to Kick Off the Year
- Do ETFs Pay Dividends? What You Need to Know
- Vistra Corp: Could 2025 Continue Its Streak of Outperformance?
- Airline Stocks – Top Airline Stocks to Buy Now
- Vertex’s Pain Drug: Big Pharma’s Next Major Success?
Receive News & Ratings for Acacia Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acacia Research and related companies with MarketBeat.com's FREE daily email newsletter.